Avanza Fonder’s Quest Diagnostics DGX Stock Holding History

Avanza Fonder’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Sell	4,877 -4,492	-48%	-$882K	0.02%	335
2026 Q1	$1.84M	Hold	9,369	–	–	0.05%	281
2025 Q4	$1.63M	Hold	9,369	–	–	0.04%	308
2025 Q3	$1.79M	Hold	9,369	–	–	0.05%	274
2025 Q2	$1.68M	Buy	9,369 +206	+2%	+$35.8K	0.05%	276
2025 Q1	$1.54M	Sell	9,163 -325	-3%	-$53.4K	0.05%	289
2024 Q4	$1.43M	Buy	+9,488	New	+$1.48M	0.04%	306

Other funds holding DGX

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Avanza Fonder's DGX Position: Q2 2026 in Review

Avanza Fonder reduced its Quest Diagnostics (DGX) stake by 48% in Q2 2026, selling an estimated $882K and leaving 4,877 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #335.

Avanza Fonder first reported a position in DGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.84M in Q1 2026. 444 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Avanza Fonder held 4,877 shares of Quest Diagnostics worth $1.03M as of Q2 2026.
Avanza Fonder sold 4,492 Quest Diagnostics shares in Q2 2026, an estimated $882K.
Quest Diagnostics made up 0.02% of Avanza Fonder's portfolio in Q2 2026, its #335 holding.
Avanza Fonder first reported a position in Quest Diagnostics in Q4 2024 and has held it in 7 quarters since.
Avanza Fonder's Quest Diagnostics position peaked at $1.84M in Q1 2026.
444 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.